XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue Recognition (Tables)
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue The following table represents Evolent’s revenue disaggregated by end-market and product type:
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2023202220232022
Medicaid$195,259 $139,718 $587,611 $410,226 
Medicare208,166 117,967 474,535 336,365 
Commercial and other107,590 94,900 345,695 222,990 
Total$511,015 $352,585 $1,407,841 $969,581 
Performance Suite$323,722 $204,727 $840,171 $583,976 
Specialty Technology and Services Suite81,230 12,400 223,598 38,854 
Administrative Services68,713 107,328 229,534 306,544 
Cases37,350 28,130 114,538 40,207 
Total$511,015 $352,585 $1,407,841 $969,581 
Schedule of Contract with Customer, Asset and Liability
The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of September 30, 2023 and December 31, 2022 (in thousands):
September 30, 2023December 31, 2022
Short-term receivables (1)
$393,782 $246,209 
Short-term deferred revenue5,763 5,758 
Long-term deferred revenue1,513 2,533 
————————
(1)Excludes pharmacy claims receivable and premiums receivable.
Changes in deferred revenue for the nine months ended September 30, 2023, are as follows (in thousands):
Deferred revenue
Balance as of beginning-of-period$8,291 
Reclassification to revenue, as a result of performance obligations satisfied(5,272)
Cash received in advance of satisfaction of performance obligations4,257 
Balance as of end of period$7,276